BerGenBio is a clinical-stage oncology company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. AXL signalling plays a crucial role both in tumour cells where it promotes immune evasion, drug resistance and cancer spread, and in immune cells where it suppresses tumour recognition and cell-killing. Therefo...
BerGenBio is a clinical-stage oncology company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. AXL signalling plays a crucial role both in tumour cells where it promotes immune evasion, drug resistance and cancer spread, and in immune cells where it suppresses tumour recognition and cell-killing. Therefore, blocking AXL activity represents a novel approach to prevent cancer survival mechanisms and to improve the efficacy of chemotherapy, targeted therapy and immuno-oncology drugs.
Upgrade this company profile// Update & customize all content. Ask PharmaCompass, click HERE.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
